AI-generated analysis. Always verify with the original filing.
Apogee Therapeutics, Inc. announced positive 52-week maintenance data from Part A of the Phase 2 APEX clinical trial of zumilokibart (APG777) in patients with moderate-to-severe atopic dermatitis, demonstrating durable maintenance and deepening of responses with 3- and 6-month dosing intervals. The company plans to initiate Phase 3 trials in the second half of 2026 based on these results and anticipated Part B data.
Event Type
Disclosure
Voluntary
Variant
8-K
of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchang
Other Events. On March 23, 2026, the Company announced positive maintenance data from Part A of the Phase 2 APEX clinical trial of zumilokibart (APG777) in pati
Financial Statements and Exhibits. (d) Exhibits . The following exhibits are being furnished herewith: EXHIBIT INDEX Exhibit No. Description 99.1 Data Press Rel